Verzenio plus Faslodex improved progression-free survival in HR+/HER2– advanced breast cancer after CDK/6i failure, with a ...

Corcept's new drug, relacorilant, shows promise with positive Phase 3 results and an FDA decision expected. Learn more about ...

Enhertu improved overall survival versus chemotherapy in HER2-positive metastatic gastric cancer, prompting an interim ...

Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) has shown clinically meaningful 'improvement' in the ...

Drugmaker AstraZeneca on Wednesday said that its experimental breast cancer treatment improved patient survival without the ...

Despite a proven survival benefit, the addition of pembrolizumab (Keytruda) to chemoradiotherapy for newly diagnosed locally ...

With cancer rising in women under 40, there's concern about the causes — and the effects. PEOPLE's editor-in-chief Charlotte ...

The drug candidate improved progression-free survival in patients, it said.

The time of day of immunotherapy infusions does appear to affect patient outcomes. But convincing the wider oncology ...

A new study published in JAMA determined that the addition of sugemalimab to chemotherapy enhances overall and ...

Since the existence of the oligometastatic disease state was posited three decades ago,1 there has been interest in ...